|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Intraductal neoplasm of the intrahepatic bile duct: Clinicopathological study of 24 cases显示文摘AIM: To investigate the clinicopathological features of intraductal neoplasm of the intrahepatic bile duct (INihB). METHODS: Clinicopathological features of 24 cases of INihB, which were previously diagnosed as biliary papillomatosis or intraductal growth of intrahepatic biliary neoplasm, were reviewed. Mucin immunohistochemistry was performed for mucin (MUC)1, MUC2, MUC5AC and MUC6. Ki-67, P53 and β-catenin immunoreactivity were also examined. We categorized each tumor as adenoma (low grade), borderline (intermediate grade), and malignant (carcinoma in situ , high grade including tumors with microinvasion). RESULTS: Among 24 cases of INihB, we identified 24 tumors. Twenty of 24 tumors (83%) were composed of a papillary structure; the same feature observed in intraductal papillary neoplasm of the bile duct (IPNB). In contrast, the remaining four tumors (17%) showed both tubular and papillary structures. In three of the four tumors (75%), macroscopic mucin secretion was limited but microscopic intracellular mucin was evident. Histologically, 16 tumors (67%) were malignant, three (12%) were borderline, and five (21%) were adenoma. Microinvasion was found in four cases (17%). Immunohistochemical analysis revealed that MUC1 was not expressed in the borderline/adenoma group but was expressed only in malignant lesions (P = 0.0095). Ki-67 labeling index (LI) was significantly higher in the malignant group than in the borderline/adenoma group (22.2 ± 15.5 vs 7.5 ± 6.3, P < 0.01). In the 16 malignant cases, expression of MUC5AC showed borderline significant association with high Ki-67 LI (P = 0.0622). Nuclear expression of β-catenin was observed in two (8%) of the 24 tumors, and these two tumors also showed MUC1 expression. P53 was negative in all tumors. CONCLUSION: Some cases of INihB have a tubular structure, and are subcategorized as IPNB with tubular structure. MUC1 expression in INihB correlates positively with degree of malignancy. | Yoshiki Naito Hironori Kusano Osamu Nakashima Eiji Sadashima Satoshi Hattori Tomoki Taira Akihiko Kawahara Yoshinobu Okabe Kazuhide Shimamatsu Jun Taguchi Seiya Momosaki Koji Irie Rin Yamaguchi Hiroshi Yokomizo Michiko Nagamine Seiji Fukuda Shinichi Sugiyama Naoyo Nishida Koichi Higaki Munehiro Yoshitomi Masafumi Yasunaga Koji Okuda Hisafumi Kinoshita Masayoshi Kage Masamichi Nakayama Makiko Yasumoto Jun Akiba Hirohisa Yano | 2012 | World Journal of Gastroenterology2012，18，28： | 16 |
| 2 | Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis显示文摘Bone is one of the preferred sites for the metastasis of malignant tumours,such as breast cancer,lung cancer and malignant melanoma.Tumour cells colonizing bone have the capacity to induce the expression of receptor activator of nuclear factor-κB ligand(RANKL),which promotes osteoclast differentiation and activation.Tumour-induced osteoclastic bone resorption leads to a vicious cycle between tumours and bone cells that fuels osteolytic tumour growth,causing bone pain and hypercalcaemia.Furthermore,RANKL contributes to bone metastasis by acting as a chemoattractant to bone for tumour cells that express its receptor,RANK.Thus inhibition of the RANKL–RANK pathway is a promising treatment for bone metastasis,and a human monoclonal anti-RANKL antibody,denosumab,has been used in the clinic.However,orally available drugs targeting RANKL must be developed to increase the therapeutic benefits to patients.Here we report the efficacy of the small-molecule RANKL inhibitor AS2676293 in treating bone metastasis using mouse models.Oral administration of AS2676293 markedly inhibited bone metastasis of human breast cancer cells MDA-MB-231-5a-D-Luc2 as well as tumour-induced osteolysis.AS2676293 suppressed RANKLmediated tumour migration in the transwell assay and inhibited bone metastasis of the murine cell line B16F10,which is known not to trigger osteoclast activation.Based on the results from this study,RANKL inhibition with a small-molecule compound constitutes a promising therapeutic strategy for treating bone metastasis by inhibiting both osteoclastic bone resorption and tumour migration to bone. | Yuta Nakai Kazuo Okamoto Asuka Terashima Shogo Ehata Jun Nishida Takeshi Imamura Takashi Ono Hiroshi Takayanagi | 2019 | Bone Research2019，7，1： | 8 |
| 3 | CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis显示文摘 | Yoshito Hayashi Masahiko Tsujii Jun Wang Jumpei Kondo Tomofumi Akasaka Ying Jin Wei Li Toru Nakamura Tsutomu Nishida Hideki Iijima Shingo Tsuji Sunao Kawano Norio Hayashi Tetsuo Takehara | 2013 | Gut2013，，11： | 2 |
| 4 | The G/G Genotype of a Resistin Single-Nucleotide Polymorphism at ?420 Increases Type 2 Diabetes Mellitus Susceptibility by Inducing Promoter Activity through Specific Binding of Sp1/3显示文摘 | Haruhiko Osawa Kazuya Yamada Hiroshi Onuma Akiko Murakami Masaaki Ochi Hiroko Kawata Tatsuya Nishimiya Toshiyuki Niiya Ikki Shimizu Wataru Nishida Mitsuru Hashiramoto Azuma Kanatsuka Yasuhisa Fujii Jun Ohashi Hideichi Makino | 2004 | The American Journal of Human Genetics2004，，4： | 1 |
| 5 | Using Whole Annealing Genetic Algorithms for the Turbine Cascade Inverse Design Problem显示文摘INTRODUCTIONInthelastfewyearstherehajsbeenagrowinginterestinthenumericalsolutionofconstrainedoptimizationproblemsofturbinegovernedbytheEulerorNavier-Stokesequations.Developmelltofturbinecascadeswithoptimumaerodynamicefficiencyhaslongbeenadesignchalle... | Jun Li Zhenping Feng Hidetoshi Nishida Nobuyuki Satofuka | 1999 | Journal of Thermal Science1999，8，1： | 1 |
| 6 | Genetic relationship among Japanese sentinel crabs (Decapoda: Ocypodidae: genus Macrophthalmus )显示文摘 | Toru Horii Jun Kitaura Keiji Wada Mutsumi Nishida | 2001 | Comparative Biochemistry and Physiology Part B2001，，1： | 1 |
| 7 | Correlation of Corneal Sensation, but not of Basal or Reflex Tear Secretion, With the Stage of Diabetic Retinopathy显示文摘 | Jun Saito Miho Enoki Makiko Hara Naoyuki Morishige Tai-ichiro Chikama Teruo Nishida | 2003 | Cornea2003，，1： | 1 |
| 8 | A replication study confirmed the EDAR gene to be a major contributor to population differentiation regarding head hair thickness in Asia显示文摘 | Akihiro Fujimoto Jun Ohashi Nao Nishida Taku Miyagawa Yasuyuki Morishita Tatsuhiko Tsunoda Ryosuke Kimura Katsushi Tokunaga | 2008 | Human Genetics2008，，2： | 1 |
| 9 | Comparison of Corneal and Aqueous Humor Penetration of Moxifloxacin, Gatifloxacin and Levofloxacin during Keratoplasty显示文摘 | Masahiko Fukuda Masakazu Yamada Shigeru Kinoshita Tsutomu Inatomi Yuichi Ohashi Toshihiko Uno Jun Shimazaki Yoshiyuki Satake Naoyuki Maeda Yuichi Hori Kohji Nishida Akira Kubota Toru Nakazawa Yoshikazu Shimomura | 2012 | Advances in Therapy2012，，4： | 1 |
| 10 | Intrahepatic biliary strictures after liver transplantation显示文摘 | Seigo Nishida Noboru Nakamura Jun Kadono Teruo Komokata Ryuzo Sakata Juan R. Madariaga Andreas G. Tzakis | 2006 | Journal of Hepato - Biliary - Pancreatic Surgery2006，，6： | 1 |
| 11 | Intrahepatic biliary strictures after liver transplantation显示文摘 | Seigo Nishida Noboru Nakamura Jun Kadono Teruo Komokata Ryuzo Sakata Juan R. Madariaga Andreas G. Tzakis | 2006 | Journal of Hepato - Biliary - Pancreatic Surgery2006，，6： | 1 |
| 12 | The combination of the expression of hexokinase 2 and pyruvate kinaseM2 is a prognostic marker in patients with pancreatic cancer显示文摘 | Hisataka Ogawa Hiroaki Nagano Masamitsu Konno Hidetoshi Eguchi Jun Koseki Koichi Kawamoto Naohiro Nishida Hugh Colvin Akira Tomokuni Yoshito Tomimaru Naoki Hama Hiroshi Wada Shigeru Marubashi Shogo Kobayashi Masaki Mori Yuichiro Doki Hideshi Ishii | 2015 | Molecular and Clinical Oncology2015，，3： | 1 |
| 13 | 99mTc-DTPA-Galactosyl-Human-Serum-Albumin Liver Scintigraphy for Evaluating Hepatic Functional Reserve Before Hepatectomy in a Patient with Indocyanine Green Excretory Defect: Report of a Case显示文摘 | Jun Kadono Hizuru Kumemura Seigo Nishida Noboru Nakamura Kentaro Gejima Masayuki Nakajo Shinsaku Tsuchimochi Jun Matsumoto Nobuo Hamada Ryuzo Sakata | 2006 | Surgery Today2006，，5： | 1 |
| 14 | Neurolytic celiac plexus block reduces occurrence and duration of terminal delirium in patients with pancreatic cancer显示文摘 | Young-Chang P. Arai Makoto Nishihara Kunio Kobayashi Tamotsu Kanazawa Nobuhiko Hayashi Yukio Tohyama Kikuyo Nishida Maki Arakawa Chiharu Suzuki Akiko Kinoshita Miki Kondo Satuki Matsubara Nami Yokoe Ruiko Hayashi Aya Ohta Jun Sato Takahiro Ushida | 2013 | Journal of Anesthesia2013，，1： | 1 |
| 15 | Current state of practice for colonic diverticular bleeding in 37 hospitals in Japan: A multicenter questionnaire study显示文摘AIM To clarify the current state of practice for colonic diverticular bleeding(CDB) in Japan.METHODS We conducted multicenter questionnaire surveys of the practice for CDB including clinical settings(8 questions),diagnoses(8 questions),treatments(7 questions),and outcomes(4 questions) in 37 hospitals across Japan.The answers were compared between hospitals with high and low number of inpatient beds to investigate which factor influenced the answers.RESULTS Endoscopists at all 37 hospitals answered the questions,and the mean number of endoscopists at these hospitals was 12.7.Of all the hospitals,computed tomography was performed before colonoscopy in 67% of the hospitals.The rate of bowel preparation was 46.0%.Early colonoscopy was performed within 24 h in 43.2% of the hospitals.Of the hospitals,83.8% performed clipping as first-line endoscopic therapy.More than half of the hospitals experienced less than 20% rebleeding events after endoscopic hemostasis.No significant difference was observed in the annual number of patients hospitalized for CDB between high-(≥700 beds) and low-volume hospitals.More emergency visits(P=0.012) and endoscopists(P=0.015),and less frequent participation of nursing staff in early colonoscopy(P=0.045) were observed in the high-volume hospitals.CONCLUSION Some practices unique to Japan were found,such as performing computed tomography before colonoscopy,no bowel preparation,and clipping as first-line therapy.Although,the number of staff differed,the practices for CDB were common irrespective of hospital size. | Ryota Niikura Naoyoshi Nagata Hisashi Doyama Ryosuke Ota Naoki Ishii Katsuhiro Mabe Tsutomu Nishida Takuto Hikichi Kazuki Sumiyama Jun Nishikawa Toshio Uraoka Shu Kiyotoki Mitsuhiro Fujishiro Kazuhiko Koike | 2016 | World Journal of Gastrointestinal Endoscopy2016，8，20： | 0 |
| 16 | Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma显示文摘BACKGROUND A well-recognized class effect of immune checkpoint inhibitors(ICI)is immune-related adverse events(IrAEs)ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI.Deaths are reported in<5%of patients treated with ICI.There are,however,no reliable markers to predict the onset and severity of IrAEs.We tested the association between neutrophil-lymphocyte ratio(NLR)and platelet-lymphocyte ratio(PLR)at baseline with development of clinically significant IrAEs(grade≥2)in hepatocellular carcinoma(HCC)patients treated with ICI.AIM To test the association between NLR and PLR at baseline with development of clinically significant IrAEs(grade≥2)in HCC patients treated with ICI.METHODS Data was extracted from an international database from a consortium of 11 tertiary-care referral centers.NLR=absolute neutrophil count/absolute lymphocyte count(ALC)and PLR=platelet count/ALC.Cutoff of 5 was used for NLR and 300 for PLR based on literature.We also tested the association between RESULTS Data was collected from 361 patients treated between 2016-2020 across the United States(67%),Asia(14%)and Europe(19%).Most patients received Nivolumab(n=255,71%).One hundred sixty-seven(46%)patients developed at least one IrAE,highest grade 1 in 80(48%),grade≥2 in 87(52%)patients.In a univariable regression model PLR>300 was significantly associated with a lower incidence of grade≥2 IrAEs(OR=0.40;P=0.044).Similarly,a trend was observed between NLR>5 and lower incidence of grade≥2 IrAEs(OR=0.58;P=0.097).Multivariate analyses confirmed PLR>300 as an independent predictive marker of grade≥2 IrAEs(OR=0.26;P=0.011),in addition to treatment with programmed cell death ligand 1(PD-1)/cytotoxic T lymphocyte-associated protein-4(OR=2.57;P=0.037)and PD-1/tyrosine kinase inhibitor(OR=3.39;P=0.01)combinations.Antibiotic use was not associated with IrAE incidence(OR=1.02;P=0.954).Patients treated with steroids had a>2-fold higher incidence of grade≥2 IrAEs(OR=2.74;P<0.001),although 74%were prescribed steroids for the treatment of IrAEs.CONCLUSION Given that high baseline NLR and PLR are associated with a decreased incidence of IrAEs,lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI.This finding is in keeping with several studies in solid tumors that have shown that baseline NLR and PLR appear predictive of IrAEs. | Sirish Dharmapuri UmutÖzbek Hiren Jethra Tomi Jun Thomas U Marron Anwaar Saeed Yi-Hsiang Huang Mahvish Muzaffar Matthias Pinter Lorenz Balcar Claudia Fulgenzi Suneetha Amara Arndt Weinmann Nicola Personeni Bernhard Scheiner Tiziana Pressiani Musharraf Navaid Bertram Bengsch Sonal Paul Uqba Khan Dominik Bettinger Naoshi Nishida Yehia Ibrahim Mohamed Arndt Vogel Anuhya Gampa James Korolewicz Antonella Cammarota Ahmed Kaseb Peter R Galle Anjana Pillai Ying-Hong Wan Alessio Cortellini Masatoshi Kudo Antonio D’Alessio Lorenza Rimassa David James Pinato Celina Ang | 2023 | World Journal of Gastrointestinal Oncology2023，15，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员